Company Filing History:
Years Active: 2024
Title: John Paul Sherrill: Innovator in CDK2 Inhibitors
Introduction
John Paul Sherrill is a notable inventor based in Melrose, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDK). His work is crucial for advancing treatments for various CDK-related diseases and disorders.
Latest Patents
Sherrill holds a patent for "CDK2 inhibitors and methods of using the same." This patent includes compounds according to Formula I or a pharmaceutically acceptable salt thereof. The patent outlines the compositions and methods for inhibiting CDK, which are essential for treating CDK-related diseases and disorders. He has 1 patent to his name.
Career Highlights
John Paul Sherrill is currently associated with Cedilla Therapeutics, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in CDK inhibitors positions him as a key player in the development of new therapeutic strategies.
Collaborations
Some of his notable coworkers include Louise Clare Kirman and Carl Eric Schwartz. Their collaborative efforts contribute to the advancement of research and development in their field.
Conclusion
John Paul Sherrill's work in CDK2 inhibitors exemplifies the impact of innovative thinking in medicine. His contributions are paving the way for new treatments that could significantly improve patient outcomes.